Crinetics Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Crinetics Pharmaceuticals şirketinin toplam hissedar öz sermayesi $833.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $937.4M ve $104.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$862.67m
Eşitlik	US$832.98m
Toplam yükümlülükler	US$104.39m
Toplam varlıklar	US$937.37m

Son finansal sağlık güncellemeleri

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14

Recent updates

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Jan 02

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CRNX 'nin kısa vadeli varlıkları ( $877.6M ) kısa vadeli yükümlülüklerini ( $53.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: CRNX şirketinin kısa vadeli varlıkları ( $877.6M ) uzun vadeli yükümlülüklerini ( $50.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CRNX borçsuzdur.

Borcun Azaltılması: CRNX un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CRNX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: CRNX serbest nakit akışı her yıl % 32.6 2.1 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/29 05:22
Gün Sonu Hisse Fiyatı	2025/01/29 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Crinetics Pharmaceuticals, Inc. 17 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Brian Skorney	Baird
Joshua Schimmer	Cantor Fitzgerald & Co.
Charles Duncan	Cantor Fitzgerald & Co.

Crinetics Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Recent updates

New major risk - Shareholder dilution

Crinetics Announces Positive Topline Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)

Chief Medical & Development Officer exercised options and sold US$528k worth of stock

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Crinetics Pharmaceuticals, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer

Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Founder notifies of intention to sell stock

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Chief Operating Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from Russell 2500 Value Index

Chief Commercial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Price target increased by 7.8% to US$66.43

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics Pharmaceuticals, Inc. Appoints Robert M. Cuddihy as Senior Vice President of Medical Affairs

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

Price target increased by 8.2% to US$61.50

Full year 2023 earnings released: US$3.69 loss per share (vs US$3.15 loss in FY 2022)

Founder notifies of intention to sell stock

Price target increased by 10% to US$59.79

Crinetics Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

Chief Development Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.8% to US$57.23

Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly

Price target increased by 9.1% to US$54.46

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Consensus revenue estimates decrease by 88%, EPS upgraded

Consensus revenue estimates decrease by 89%, EPS upgraded

Chief Medical Officer notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Chief Medical Officer notifies of intention to sell stock

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly

Price target increased by 8.2% to US$46.78

Consensus revenue estimates fall by 18%

Price target decreased by 7.4% to US$43.63

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$1.0m worth of stock

Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023

Founder notifies of intention to sell stock